1. Scrip
  2. >>Focus On Asia

Eisai Refiles Mecobalamin For ALS In Japan After Seven Years

 
• By Lisa Takagi

Additional studies have shown an ultra-high dose of mecobalamin safely decreased ALS progression in early-stage patients by 43%. Japan has spent decades studying the drug’s efficacy for the disease.

If approved, mecobalamin can expand the treatment option for early ALS patients.
mecobalamin would expand ALS options in Japan if approved • Source: Shutterstock

Eisai Co., Ltd. has refiled for the approval of an ultra-high dose of mecobalamin (E0302) for the treatment of amyotrophic lateral sclerosis (ALS) in Japan, following its withdrawal of a previous application several years ago due to insufficient clinical data.

If approved, the country would be the first globally clear the injected drug for ALS, for which several other oral...

More from Japan

More from Focus On Asia